The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
Abstract
A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Davis, S. T., Benson, B. G., Bramson, H. N., Chapman, D. E., Dickerson, S. H., Dold, K. M., Eberwein, D. J., Edelstein, M., Frye, S. V., Gampe, R. T., et al. (2001) · Science · doi:10.1126/science.291.5501.134 · Cited by 166
RetractedThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids
Holland, B. T., Blanford, C. F., & Stein, A. (1998) · Science · doi:10.1126/science.281.5376.538 · Cited by 1,484
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Research works printed but not linked: 46
- Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
- Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
- Fry D. W., 2000, Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs, 2, 59
- Gray N., 1999, Curr. Med. Chem., 6, 875
- Fry D. W., 2001, J. Biol. Chem., 276, 16623
- Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
- Chang Y.-T., 1999, Chem. Biol., 6, 375
- Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
- Zaharevitz D. W., 1999, Cancer Res., 59, 2569
- Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
- Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
- Kim K. S., 2002, J. Med. Chem., 45, 3927
- Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
- Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
- Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
- Seong Y.-S., 2003, Cancer Res., 63, 7391
- Kim K. S., 2000, J. Med Chem., 43, 4134
- Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
- Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
- Yue E. W., 2002, J. Med. Chem., 45, 5248
- Lane M. E., 2001, Cancer Res., 61, 6177
- Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
- Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
- Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
- Honma T., 2001, J. Med. Chem., 44, 4627
- Honma T., 2001, J. Med. Chem., 44, 4640
- Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
- Zhu G., 2003, J. Med. Chem., 46, 2030
- Bartek J., 2003, Biochem. J., 371, 204
- Bartkova J., 1997, Prog. Cell Cycle Res., 3, 220
- Hall M., 1996, Adv. Cancer Res., 68, 108
- Misra R. N., 2004, Chem
- Kelland L. R., 2000, Exp. Opin. Invest. Drugs, 9, 2911
- Chao S.-H., 2001, J. Biol. Chem., 276, 31799
- Chao S.-H., 2000, J. Biol. Chem., 275, 28348
- Tetsu O., 2003, Cancer Cell, 2, 245
- Fry D. W., 2004, Mol. Cancer Ther., 3, 1437
- Meyerson M., 1994, Mol. Cell Biol., 14, 2086
- Fry D. W., 1994, Anticancer Drug Des., 9, 351
- Fry D. W., 1997, Biochem. Pharmacol., 54, 887
Cited by
Items 401–500 of 555
Rooney, T. P. C., Aldred, G. G., Winpenny, D., Scott, H. E., Willems, H. M. G., Voytyuk, I., Clarke, J. H., Boffey, H. K., Andrews, S. P., & Skidmore, J. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00579 · Cited by 5
He, S., Meister, D. L., Khan, S., Mohammadzadeh, A., Delgadillo-Silva, L. F., Rutter, G. A., Trant, J. F., & Lim, G. E. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08150-6 · Cited by 5
Three-dimensional structure of the palbociclib–HIV TAR complex
Ramireddy, R. R., Vidalala, V., Chaubey, B., Olsen, G. L., & Varani, G. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag129 · Cited by 4
“We show here that palbociclib induces a completely new structure in TAR, unlike the “Tat free” or “Tat bound” structures described before [ 27 –32 ], to create a deep binding pocket reminiscent of small-molecule binding sites in enzymes such as its clinical target cdk6 [ 33 ].”
Safaroghli‐Azar, A., Mekonnen, L. B., Lenjisa, J. L., Milne, R. W., & Wang, S. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01794-7 · Cited by 5
“Palbociclib (Ibrance/PD-0332991) , the first-in-class CDK4/6 inhibitor developed by Pfizer [247, 248], shows potent selectivity for CDK4/cyclin D1, CDK4-cyclin D3, and CDK6-cyclin D2 with the IC 50 of 11 nM, 9 nM, and 15 nM, respectively.”
Udayasri, A., Ramakrishna, D. S., Behera, P., Praveen, P. L., & Brahmeswararao, M. V. N. (2023) · Journal of Molecular and Engineering Materials · doi:10.1142/s2251237324400112 · Cited by 4
Liu, W., Huang, Y., Wu, L., Liu, W., Jiang, X., Xu, Z., & Zhao, Q. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03667c · Cited by 4
Delgado, M., Washam, C. L., Urbaniak, A. J., Heflin, B., Storey, A. J., Lan, R. S.-L., Mackintosh, S. G., Tackett, A. J., Byrum, S. D., & Chambers, T. C. (2021) · ACS Omega · doi:10.1021/acsomega.1c03936 · Cited by 3
Alshargabi, T. Q., Helmy, M. W., Soliman, S. M., Haukka, M., Barakat, A., Hagar, M., Marie, M. G., Mohamed, S. A., Osman, D. H., & Bekhit, M. G. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143040 · Cited by 3
Wu, Y., Chmiel, A. F., & Bronson, J. J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03492 · Cited by 4
Kamal, Ä., Nekkanti, S., Shankaraiah, N., & Sathish, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_27 · Cited by 4
Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report
Horie, T., Kijima, T., Yamaguchi, M., Honda, S., Horie, M., Ishitobi, K., Yamagata, S., Sakano, S., & Kurokohchi, K. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2223 · Cited by 3
CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes
Lee, S., Rodriguez, L. R. L., Majumdar, R., de Marval, P. L. M., & Rodríguez‐Puebla, M. L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12993 · Cited by 3
A Compendium of Tyrosine-kinase Inhibitors: Powerful and Efficient Drugs against Cancer
Costa, D. C. S., Forezi, L. D. S. M., Cardoso, M. F. D. C., Ribeiro, R. C. B., Pinto, A. C., Ferreira, V. F., & da Silva, F. D. C. (2017) · Revista Virtual de Química · doi:10.21577/1984-6835.20170063 · Cited by 3
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics
Malumbres, M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_10 · Cited by 5
Future Directions in Pancreatic Cancer Therapy
Orchard‐Webb, D. (2015) · Università degli Studi di Napoli Federico II · doi:10.6092/1590-8577/2991 · Cited by 3
“Pfizer (palbociclib) [25], Novartis/ Astex Pharmaceuticals (LEE011) and Eli Lilly (abemaciclib) [26], have developed orally administered potent small molecule inhibitors of CDK4/6.”
BackgroundNovel Therapeutic Approaches and Targets for Ovarian Cancer
Previs, R. A., Mills, G. B., & Westin, S. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813209-8.00034-0 · Cited by 6
New Chemical Entities Entering Phase III Trials in 2013
Notte, G. T. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00026-2 · Cited by 3
Recent developments in the synthesis of tricyclic condensed pyrimidinones
Naikoo, R. A., Kumar, R., Kumar, V., & Bhargava, G. (2021) · Synthetic Communications · doi:10.1080/00397911.2021.1885718 · Cited by 3
Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways
Reid, A. H. M., Baird, R. D., & Workman, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_17 · Cited by 3
Kinase Inhibitors: Approved Drugs and Clinical Candidates
Bradbury, R. H. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc214 · Cited by 3
Hafner, M. A., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/211680 · Cited by 3
Research progress of dual-targeting CDKs regulators for cancer therapy
Yue, F.-X., Wang, Y., Rui-Yan, Chen, G., Li, X., & Shen, Q. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108769 · Cited by 2
Zhang, R., Yu, T., Zhang, M., Li, J., Gu, A., Aimaiti, M., Li, S., He, H., Liu, Y., & Li, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01886 · Cited by 2
Evteev, S. A., Ivanenkov, Y. A., Aiginin, A., Kuznetsov, M., Shayakhmetov, R., Knyazev, M., Bezrukov, D. S., Малышев, А. В., Malkov, M., Aliper, A., et al. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70056 · Cited by 2
“Compound 1 is the TTK inhibitor with nanomolar potency described previously [33], while compounds 2–4 and 5 (palbociclib), 7 and 8 (ribociclib) were reported as kinase inhibitors, especially against CDK4 and CDK6 [34, 35].”
Knudsen, E. S., O’Connor, T. N., & Witkiewicz, A. K. (2025) · Cancer Heterogeneity and Plasticity · doi:10.47248/chp2502030015 · Cited by 5
“Selective CDK4/6 inhibitors were first reported over 20 years ago [104,105].”
Regulation of p53 Activity and Associated Checkpoint Controls
Post, S. M., Quintás‐Cardama, A., & Lozano, G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-178-3_11 · Cited by 2
Brett, J. O., Herman, P. E., Mayer, E. L., Bardia, A., & Wander, S. A. (2022) · Current Breast Cancer Reports · doi:10.1007/s12609-022-00461-3 · Cited by 2
Efficacy and Predictability of Cyclin-Dependent Kinase 4/6 Inhibitors in HER2-Positive Breast Cancer
Abbasi, M. S., Afzal, M. Z., Sarwar, T., & Gamlen, H. A. (2025) · Cancers · doi:10.3390/cancers17172788 · Cited by 2
A new and efficient protocol for the synthesis of the key intermediate of Palbociclib
Li, S., Yang, W., Ji, M., Cai, J., & Chen, J. (2019) · Journal of Chemical Research · doi:10.1177/1747519819831858 · Cited by 2
Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects
Li, X. (2022) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-022-02599-x · Cited by 2
Post-GWAS Validation of Target Genes Associated with HbF and HbA2 Levels
Caria, C. A., Faà, V., Porcu, S., Marongiu, M. F., Poddie, D., Perseu, L., Meloni, A., Vaccargiu, S., & Ristaldi, M. S. (2024) · Cells · doi:10.3390/cells13141185 · Cited by 3
“…at: https: //www.mdpi.com/article/10.3390/cells13141185/s1, Figure S1 S1: Gene name, sequence and application of primers used in this study; Table S2: data from RT-qPCR on ln72 Ccnd3 mice; Table S3: data from RT-qPCR on ln72 Nfix mice; Table S4: Hematological parameters of ln72 Ccnd3 mice; Table S5”
MethodInfluentialTargeting Cyclin-Dependent Kinases for Cancer Therapy
Johnson, N., & Shapiro, G. I. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1770-6_11 · Cited by 2
Divya, V., & Pushpa, V. L. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.108020 · Cited by 2
Hards, R., Howarth, C. L., Wiredu, K., LaCroix, I. S., del Valle, J. M., Adamo, M. E., Kettenbach, A. N., Holland, A. J., & Gerber, S. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.08.471812 · Cited by 2
“Extensive drug discovery efforts were required to generate more selective inhibitors of Cdk1 [20] and Cdk4/6 [21].”
BackgroundOstapenko, D., Li, H., Trier, I., Shamby, R., Wang, Y., Zagoren, E., Sabrera, C. B., Sumigray, K., Alarcón, C. R., & Kabeche, L. (2026) · Nature Communications · doi:10.1101/2025.10.20.683416 · Cited by 2
Bittner, M., Llauradó, M., Hoenisch, J., Leung, Y., Kim, H., Wong, N. K. Y., Pishas, K. I., Cheasley, D. A., Cowley, K. J., Simpson, K. J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041774 · Cited by 2
“CDK4/6i were developed to selectively block CDK4/6 activity, targeting cancers driven by aberrant CDK4/6-cyclin D1 signaling [32].”
Souza, I. L. M., Torres, A. C. M. B. G., Lucas, R., Jiacomini, I. G., Klein, S. R., Reis, M. B. E., Suzukawa, A. A., Zanette, D. L., Aoki, M. N., de Aguiar, A. M., et al. (2026) · Cells · doi:10.3390/cells15050446 · Cited by 1
CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance
Sha, W., Feng, D., Yan, Z., Chen, Z., & Lu, Y. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118736 · Cited by 2
Klapp, V., Bloy, N., Jiménez‐Cortegana, C., Buqué, A., & Petroni, G. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.02.018 · Cited by 2
CDK4/6 inhibitors display a class effect in inducing differentiation of neuroblastoma cells
Ferguson, K. M., Grealy, F. M. Y. A., & Philpott, A. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.23190.1 · Cited by 1
“4.”
Ramireddy, R. R., Shortridge, M. D., Vidalala, V., Chaubey, B., Tang, C., Olsen, G. L., & Varani, G. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag186 · Cited by 1
“The affinities of Palbociclib for TAR ( K d ∼ 3–30 nM) and cdk6 (Ki ∼ 60 nM) [ 42 ] are comparable, yet kinase inhibition was only achieved through a decade-long medicinal chemistry effort.”
InfluentialZhao, W., Bie, B., Wang, J., Liu, X., Fang, H., & Niu, R. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03588-5 · Cited by 2
Bora, CEP192 and Cenexin regulate distinct Plk1-dependent cell and centrosome cycle transitions
Dwivedi, D., Borges, C., Harry, D., Cirillo, L., & Meraldi, P. (2026) · Nature Communications · doi:10.1038/s41467-026-75033-5 · Cited by 1
Solimando, D. A., & Waddell, J. A. (2015) · Hospital Pharmacy · doi:10.1310/hpj5007-578 · Cited by 1
Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies
Alexander, A., & Keyomarsi, K. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-8039-6_14 · Cited by 2
Targeting the DNA damage response through TBL1X in mantle cell lymphoma
Pray, B. A., Baiocchi, E., Leon, S., Barta, B., Koirala, S., Tsyba, L., Hinterschied, C., Carvajal‐Moreno, J., Hout, I., Nishat, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015769 · Cited by 1
Gupta, M., & Мадан, А. К. (2013) · Journal of Chemical Sciences · doi:10.1007/s12039-013-0410-1 · Cited by 1
The study of the interaction of 4,6-dichloropyrimidine-5-carbaldehyde with glycine esters
Zinchenko, A. M., Музычка, Л. В., Білецький, І. І., & Smolii, O. B. (2018) · Journal of organic and pharmaceutical chemistry · doi:10.24959/ophcj.18.935 · Cited by 1
Historia de los receptores hormonales y de la terapia hormonal en cáncer de mama
Guerra, L. M. B., Rodríguez-Orihuela, D. L., Soto‐Pérez‐de‐Celis, E., & Chávarri-Guerra, Y. (2021) · Medicina · doi:10.56050/01205498.1594 · Cited by 5
Lv, H., Du, Y., Sheng, X., Gao, Z., & Shen, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0393 · Cited by 1
Li, L., Chen, F., Li, M., Liao, Y., Wang, Y., Jiang, W., Luan, Y., & Xia, X. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01385-0 · Cited by 1
“Palbociclib was a selective CDK4/6 inhibitor developed by Pfizer [8], which became the first approved CDK4/6 inhibitor in 2015 for the treatment of postmenopausal women with HR + /HER2 − advanced metastatic breast cancer in combination with letrozole [9].”
BackgroundCDK Inhibitors as Anticancer Agents
Yap, T. A., Molife, L. R., & Bono, J. S. D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_6 · Cited by 1
Molecular-Targeted Therapy for Melanoma
RUSSO, A. E., Bevelacqua, Y., Marconi, A., Veronesi, A., & Libra, M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_20 · Cited by 1
Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development
Molife, R., Collins, I., Workman, P., & Kaye, S. B. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap315 · Cited by 1
Hafner, M. A., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3285804 · Cited by 1
Awada, A. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732542880.793559049 · Cited by 1
A functional map of CDK-drug interactions at single amino acid resolutionPreprint
Gould, S. I., Acosta, J., Bielo, L. B., Jaboldinov, A., Johnson, G. A., Contreras, M. E., Wuest, A. N., Brémont, E., Toure, M. A., Xiang, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.02.685764 · Cited by 2
“…3 ( CDK2/4/6 ) variants were screened in the presence of three clinically approved CDK4/6 inhibitors, (i) Ribociclib ( 72 ), (ii) Palbociclib ( 73 ), and (iii) Abemaciclib ( 17 ), as well as (iv) Atirmociclib ( 74 ), a CDK4-selective, clinical-grade compound, and (v) INX-315 ( 75 ), and (vi)…”
Discovery and Design of Protein Kinase Inhibitors: Targeting the Cell Cycle in Oncology
Mezna, M., Kontopidis, G. A., & McInnes, C. (2011) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633470.ch8
Cyclin D1-AR Crosstalk: Potential Implications for Therapeutic Response in Prostate Cancer
Schiewer, M. J. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada564541
Porquet, M. Z. (2010) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Lehn, S. (2013) · Lund University Publications (Lund University) · Cited by 1
Inhibiting Cell Cycle Kinases in Cancer Therapy
de Cárcer, G., de Castro, I. P., & Malumbres, M. (2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608054640113060009
“PD0332991 displays a high level of selectivity for CDK4/6 versus over 36 other kinases [37, 44].”
BackgroundJohnson, S. M. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/996y-nn68
Regulation of the G1-S transition by cyclin-dependent kinase inhibitors
Ramsey, M. R. (2007) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/sfvt-t742
Castrellon, A. B., Nguyen, S. M., & Raez, L. E. (2017) · Archives in Cancer Research · doi:10.21767/2254-6081.1000123
“CDK4/6 in palbociclib and ribociclib, and over 160-fold less potency in abemaciclib [7,13,14].”
BackgroundAntineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2017) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub3
Johnston, S. R. D. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.06.016
“Palbociclib is an orally bioavailable small-molecule inhibitor of CDK 4 and 6 [3].”
BackgroundInfluence of PD-0332991 treatment on cell cycle regulatory genes in breast cancer stem cells
Çağlar, H. O., Süslüer, S. Y., Gündüz, C., & Haydaroğlu, A. (2018) · Ege Tıp Dergisi · doi:10.19161/etd.414615
Chauhan, J. H., & Ram, H. K. (2019) · International Journal of Scientific Research in Science Engineering and Technology · doi:10.32628/ijsrset207266
Portales, A. E. (2020) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/108071
US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
Yu, M., Tadesse, S., & Wang, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc214.pub2
Cole, K. P. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc032.pub3
Cyclin-dependent kinase inhibitors in cancer: bioanalysis and pharmacokinetics
Chávez, D. A. M. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/1012
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2022) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub4
Baker, S. J., & Reddy, E. P. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101949-1
Baker, S. J., & Reddy, E. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101949
Endicott, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737072659.793569640
Ramsey, M. R., Krishnamurthy, J., Pei, X., Torrice, C., Lin, W., Carrasco, D. R., Ligon, K. L., Xiong, Y., & Sharpless, N. E. (2023) · doi:10.1158/0008-5472.c.6495311
Ramsey, M. R., Krishnamurthy, J., Pei, X., Torrice, C., Lin, W., Carrasco, D. R., Ligon, K. L., Xiong, Y., & Sharpless, N. E. (2023) · doi:10.1158/0008-5472.c.6495311.v1
Type I IFN expression is inhibited during cell division by CDK4/6Preprint
Sumner, R. P., Ellis, A., Lant, S., Ashby, H., Towers, G. J., & de Motes, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.15.537049
“CDK4/6 inhibitors target the ATP-binding domains of CDK4 and 6 (Toogood et al, 2005), suggesting their kinase activity is likely required for IFN regulation.”
BackgroundCorey, E. J., & Wu, Y.-J. (2023) · Wiley eBooks · doi:10.1002/9781394207145.ch6
Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4 · Cited by 1
Targeting CDK4 and CDK6 in hormone-dependent cancers
Bobbitt, J. R., & Keri, R. A. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.10.006
Dual Inhibitors of CDK4 /6 for Treating Cancer
Toogood, P. L. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch22
Self-citationCurrent progress in targeting mitotic kinases in PDAC
Barlow, T. M. A., Rooman, I., & Ballet, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00162e
Zhang, F., Boutin, L., Das, I., Melief, J., Singh, M., Stantic, M., Zhang, L., Alzrigat, M., Azimi, A., Baldran-Groves, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.04.663080
Jiang, Y., Tang, Z., Zheng, W., & Xiao, X. H. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2542720
Gu, J., Dai, Z., Shen, T., Chen, X. '., Yang, Z., Sun, S., Chen, D., Luo, H., Wang, X., & Xu, J. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.38 · Cited by 6
CDK4/6 inhibitors for the treatment of breast cancer
Ayush, S., Snehal, P., Singh, R. M., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33653-9.00008-9
HER2-positive (HER2+) & HER2-negative (HER2−) targeted therapies
Bambal, V., Rathore, S. S. S., Jenita⃰, J. J. L., Paul, P., Singh, P. K., & Kenchappa, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33349-1.00006-5
Molecular Genetic Studies of Sporadic and MEN1-Associated Endocrine Pancreatic Tumors
Lindberg, D. M. (2007) · Uppsala University Publications (Uppsala University)
Annulation of diverse enamides with an aromatic propargyl ester
Wang, J., Chen, W., Zhang, Y., Xiong, F., Chen, Z., Zhan, J., Cai, X., Yue, X., & Ma, X. (2026) · Tetrahedron · doi:10.1016/j.tet.2026.135137
Sharma, D., Samreen, A., Nair, A., & Arumugam, S. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00585-9
“However, only Malassezione avoids ALARM NMR alerts, which frequently indicate problematic reactivity in early screen - ing phases and are considered unstable chemical moieties during early-stage drug discovery (Toogood et al. 2005).”
Development of fluorescent biosensors for probing CDK/Cyclin activity in vitro and in cellulo
Van, N. B. (2013) · theses.fr (ABES) · doi:10.70675/773f35d9z12daz40f0zbbb0z17ad328120a1
Ballester, M. A. (2019) · theses.fr (ABES) · doi:10.70675/9b18708ez95f5z42adz9479z32a97604ddcf
The Role of Cancer Stem Cells in Drug Resistance and Relapse
Rautela, T., Raval, D., Maheshwari, V. D., Banerjee, J., & Banerjee, S. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_2
CDK4/6 inhibitors: chemistry, pharmacology and in-silico perspectives
Mishra, S., Pandey, S., Dubey, A., Singh, N., Upadhyay, A., & Kumar, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44611-5.00005-5
Evaluation of Potential Second-Generation Manufacturing Routes to Palbociclib
Dubbaka, S. R., Rasiņa, D., Ūdris, N., Šmits, G., Jirgensons, A., Subramanian, P., Subramanian, K., Anandan, S., Graham, S. J., Fussell, S. J., et al. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.6c00245
Wang, C., Zhang, Y., Bao, S., Huang, X., Wang, C., & Zhang, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110565
Metadata
- Authors
- Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., Brodfuehrer, J., Choi, C., Barvian, M. R., & Fry, D. W.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Toogood, Peter L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-02
- Volume
- 48
- Issue
- 7
- Pages
- 2388-2406
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1985389450
- Cited by
- 513
- References
- 50
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 20 · 2023: 25 · 2022: 38 · 2021: 32 · 2020: 32 · 2019: 30 · 2018: 44 · 2017: 42 · 2016: 34 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6, CDK4/6 inhibitors, kinase selectivity, G1 cell cycle arrest, palbociclib, small-molecule kinase inhibitors, anticancer drug candidates, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Biological Availability, Humans, Male, Piperazines, Proto-Oncogene Proteins, Pyridines, Pyrimidines, Structure-Activity Relationship, Thymidine, G1 Phase, Rats, Sprague-Dawley, Cyclin-Dependent Kinases, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.